MediciNova, Inc.(MNOV)Earnings, Financials & Key RatiosMediciNova, Inc. (MNOV) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's persistent quarterly operating losses of roughly $3 million and the steady decline in cash reserves to $30.8 million suggest that the firm faces substantial liquidity risks without a clear path to commercial profitability.
MediciNova, Inc. (MNOV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
MediciNova, Inc. (MNOV) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.05vs $0.06+16.7% | $186,984vs $186,984+0.0% |
| Q1 2026 | Feb 20, 2026 | $0.05vs $0.10+47.4% | $151,000vs $151,739-0.5% |
| Q4 2025 | Nov 12, 2025 | $0.06vs $0.08+25.0% | $123,319 |
| Q3 2025 | Aug 14, 2025 | $0.07vs $0.07+0.0% | $134,599 |
Recent stock market news and headlines for MediciNova, Inc. (MNOV)
LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D.
Key metrics vs top competitors for MediciNova, Inc. (MNOV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.44 | $70.88M | -6.00 | — | -2928.78% | -25.5% | — | |
| $3.67 | $263.23M | 11.12 | -31.8% | 21.61% | 10.62% | — | |
| $4.16 | $71.91M | -3.10 | — | -1070.26% | — | — | |
| $2.71 | $251.14M | -5.02 | — | — | -38.76% | — | |
| $4.34 | $17.12M | -0.17 | — | — | -381.01% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — |
MediciNova, Inc. (MNOV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MediciNova, Inc. (MNOV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Feb 20, 2026·SEC
Dec 30, 2025·SEC
Aug 1, 2025·SEC
Get notified when MNOV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MediciNova, Inc. (MNOV) stock FAQ — growth, dividends, profitability & financials explained
MediciNova, Inc. (MNOV) reported $0.6M in revenue for fiscal year 2025.
MediciNova, Inc. (MNOV) reported a net loss of $11.7M for fiscal year 2025.
MediciNova, Inc. (MNOV) has a return on equity (ROE) of -25.5%. Negative ROE indicates the company is unprofitable.
MediciNova, Inc. (MNOV) had negative free cash flow of $9.5M in fiscal year 2025, likely due to heavy capital investments.
